Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 04 - 29 tags : Treatment save search
Eloxx Pharmaceuticals Adds Additional Treatment Arm to Ongoing Phase 2 Clinical Studies for Cystic Fibrosis
Published: 2021-04-29 (Crawled : 02:00) - globenewswire.com
ELOX | $0.8025 -51.57% 93K
|
Health Technology
|
| O: -1.4%
H: 3.77%
C: 2.83%
treatment phase 2 ongoing fibrosis cystic fibrosis
Neuronetics To Present Clinical Data at The American Psychiatric Association 2021 Annual MeetingNeuronetics will share real-world clinical data on its NeuroStar® Advanced Therapy treatment during the virtual event
Published: 2021-04-29 (Crawled : 14:00) - biospace.com/
STIM | $3.865 3.34% 3.23% 41K
|
Health Technology
|
| O: 2.34%
H: 0.0%
C: -7.95%
treatment therapy
Aerie Pharmaceuticals Completes Enrollment of its Phase 2b Clinical Trial of AR-15512 (TRPM8 Agonist) Ophthalmic Solution for the Treatment of Patients with Dry Eye Disease
Published: 2021-04-29 (Crawled : 14:00) - biospace.com/
AERI | $15.25 0.0%
|
Health Technology
|
| O: -0.11%
H: 2.16%
C: -1.36%
dry eye disease treatment phase 2 eye eye disease phase 2b trial enroll
AtriCure’s EPi-Sense System Approved by FDA for Treatment of Long-Standing Persistent Afib Patients
Published: 2021-04-29 (Crawled : 14:00) - biospace.com/
ATRC | $23.14 1.89% 1.86% 950K
|
Health Technology
|
| O: 2.93%
H: 10.63%
C: 5.7%
treatment fda approval
BrainsWay Announces Launch of Noninvasive Treatment for Smoking Addiction to U.S. Providers
Published: 2021-04-29 (Crawled : 13:15) - globenewswire.com
BWAY | $4.89 2.95% 2.86% 28K
|
Health Technology
|
| O: -0.23%
H: 0.91%
C: -1.94%
treatment
Inozyme Pharma Publishes Data Supporting INZ-701 as a Potential Treatment for ENPP1 Deficiency
Published: 2021-04-29 (Crawled : 12:00) - globenewswire.com
INZY | $4.42 0.68% 0.68% 740K
|
Health Technology
|
| O: 1.23%
H: 3.1%
C: 1.38%
treatment potential pharma
Atea Pharmaceuticals Announces First Patient Dosed in Global Phase 3 MORNINGSKY Trial of AT-527 for Treatment of COVID-19
Published: 2021-04-29 (Crawled : 08:00) - biospace.com/
AVIR | $3.725 1.5% 1.48% 180K
|
Health Technology
|
| O: 1.58%
H: 0.44%
C: -2.55%
covid treatment phase 3 trial at-527
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.